Masters of Immunology
Benjamin P. Davis and Marc E. Rothenberg
Cancer Immunol Res January 1 2014 2 (1) 1-8; DOI:10.1158/2326-6066.CIR-13-0196
Min and Hodi report that a patient with metastatic mucosal melanoma that was resistant to temozolomide and ipilimumab has experienced a durable near complete response to MK-3475 anti-PD1 therapy with associated autoimmune-related adverse events.
In a comprehensive analysis of the agonistic activity of anti-human CD40 mAb CP-870,893, Richman and Vonderheide show that Fc-crosslinking of CP-870,893 is not required. In contrast, the therapeutic potency is more dependent on the CD40 epitopes recognized.
Chapuis, Afanasiev, and colleagues show that the combined regimen of local tumor-targeted preconditioning and systemic immune therapies elicited a durable complete response in two of three lesions with a prolonged period without development of additional distant metastasis.
Odunsi and colleagues show that the DNA methyltransferase inhibitor decitabine augmented the efficacy of the NY-ESO-1 vaccine and doxorubicin treatment of patients with refractory epithelial ovarian cancer, demonstrating the potential of the combined chemo-immunotherapy regimen.
Using mouse models of lung cancer, Ortiz and colleagues show that immature myeloid cells with the phenotype of myeloid-derived suppressive cells but lacking immune suppressive activity accumulate during lung inflammation and may contribute to cancer development.
Bassiri and colleagues demonstrate that the cytotoxic responses of invariant natural killer T (iNKT) cells are sufficient to limit the growth of T lymphomas, highlighting the potential utility of iNKT cells in the immunotherapy of CD1d+ cancers.
Callahan and colleagues show that RAF inhibitors can potentiate T-cell activation by increasing T-cell expansion and ERK signaling, and when combined with CTLA-4 blockade show superior tumor control in two transplantable mouse tumor models.
Comparing the efficacy and biodistribution of local and systemic delivery of anti-CD40 agonistic antibodies, Sandin and colleagues show that local low-dose antibody therapy is effective against disseminated bladder cancer with reduced toxic side effects.